Use of intravenous immunoglobulins as an adjunct in the conservative management of chylothorax.
Two children who developed chylothorax after surgery for congenital heart disease are presented. The conservative management of chylothorax is reviewed and the use of immunoglobulins in the treatment of sepsis is discussed. One patient survived.
Mohan
H
H
Department of Cardiothoracic Anaesthesia, Freeman Hospital, Freeman Road,Newcastle upon Tyne, UK.
Paes
M L
ML
Haynes
S
S
D000900:Anti-Bacterial Agents; D001922:Brain Abscess / Q000188:drug therapy; D002675:Child, Preschool; D002916:Chylothorax / Q000628:therapy*; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D005500:Follow-Up Studies; D006330:Heart Defects, Congenital / Q000601:surgery; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007231:Infant, Newborn; D010996:Pleural Effusion / Q000628:therapy; D018700:Pleurodesis; D011183:Postoperative Complications / Q000628:therapy; D018805:Sepsis / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D013212:Staphylococcus epidermidis
D000900:Anti-Bacterial Agents; D016756:Immunoglobulins, Intravenous